Leaked IPR Draft Revives India’s Data Protection Bogey?
This article was originally published in PharmAsia News
A leaked final draft of India's national intellectual property rights (IPR) policy suggests creating an "appropriate framework" for protection of undisclosed information submitted in the drug approval process, though it does not endorse data exclusivity.
You may also be interested in...
Novartis counters speculation around pandemic-related staff cutbacks in India, saying that it actually upped the number of hires across its operations since January 2020. A senior executive separately provides a buoyant outlook for the Swiss firm’s global services operations in Hyderabad, which has added a significant number of new roles.
Lundbeck seeks to ward off Alembic and Hetero over alleged patent infringing activity pertaining to its depression therapy vortioxetine in India. The product is seen as one of the key drivers of growth in 2021 for the Danish company, which has settled infringement proceedings with over half a dozen generic opponents so far in the US.
All eyes are on a fundraising plan by Glenmark’s US innovation spin-out Ichnos, with management signaling that its proprietary BEAT platform will be the biggest value driver rather than any individual pipeline asset. The company's India business rang in a strong Q3, with remogliflozin and combinations expected to emerge as a significant franchise.